Drug Trial Radar · NCT00547651
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Last checked: Nov 19, 2026Latest source record: Nov 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
637
Actual
Start
Sep 1, 2007
Primary completion
May 1, 2011
Study completion May 1, 2011
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 22, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study drug (Amrubicin) is believed to work by stopping the tumor cells in your body from growing. The purpose of this study is to evaluate the effect of amrubicin compared to topotecan in the treatment of small cell lung cancer.
Conditions
- Small Cell Lung Cancer
Interventions
AmrubicinDrug
Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
TopotecanDrug
Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objective is to demonstrate superiority in overall survival of amrubicin compared with topotecan hydrochloride in patients with small cell lung cancer (SCLC) after failure of first-line chemotherapy.Time frame: Until death from any cause
Locations
140 sites in 17 countries. Site status is shown where the registry gives one.
Northwest Alabama Cancer Center
Muscle Shoals, Alabama
Arizona Oncology Associates
Tucson, Arizona
Little Rock Hematology Oncology Associates
Little Rock, Arkansas
Cancer Care Associates of Fresno Medical Group, Inc.
Fresno, California
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California
University of Colorado Health Science Centre
Aurora, Colorado
Rocky Mountain Cancer Center - Midtown (Main)
Denver, Colorado
Advanced Medical Specialties
Miami, Florida
Ocala Oncology Center
Ocala, Florida
Cancer Centers of Florida, P.A.
Ocoee, Florida
Florida Oncology Associates
Orange Park, Florida
Sacred Heart Medical Oncology
Pensacola, Florida
Medical Oncology Associates of Augusta
Augusta, Georgia
Joliet Oncology-Hematology Associates, Ltd.
Joliet, Illinois
Cancer & Hematology Specialists of Chicago (Main)
Niles, Illinois
Illinois Cancer Care
Peoria, Illinois
Cancer Care at Blessing Hospital
Quincy, Illinois
Central Indiana Cancer Centers
Indianapolis, Indiana
Hope Center
Terre Haute, Indiana
Kansas City Cancer Center (Main)
Overland Park, Kansas
Cancer Center of Kansas
Wichita, Kansas
Jayne Gurtler MD, Laura Brizn MD, Angelo Russo MD, and Janet Burroff MD, APMC
Metairie, Louisiana
Tulane University Health Sciences Center
New Orleans, Louisiana
Maine Center for Cancer Medicine and Blood Disorders
Scarborough, Maine
Sinai Hospital of Baltimore, Inc.
Baltimore, Maryland
Center for Cancer and Blood Disorders
Bethesda, Maryland
Alliance Hematology Oncology, P.A. (Main)
Westminster, Maryland
Kalamazoo Hematology and Oncology
Kalamazoo, Michigan
Michigan Hematology & Oncology Institute
Southgate, Michigan
University of Minnesota Medical Center, Cancer Center
Minneapolis, Minnesota
Missouri Cancer Associates
Columbia, Missouri
St. Joseph Oncology, Inc.
Saint Joseph, Missouri
Comprehensive Care Centers of Nevada (Main)
Las Vegas, Nevada
New York Oncology Hematology, P.C.
Latham, New York
SUNY Upstate Medical University - Regional Oncology Center
Syracuse, New York
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Regional Cancer Care
Durham, North Carolina
Cancer Centers of North Carolina (Main)
Raleigh, North Carolina
Piedmont Hematology Oncology Associates
Winston-Salem, North Carolina
Gabrail Cancer Center
Canton, Ohio
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.